



# GO EXPONENTIAL

## Accelerate the pace of discovery with the power of Linked-Reads

In a world of incremental improvements, true breakthroughs are born from massive leaps forward. The genomics community is not about shifting paradigms but shattering them. With Linked-Read sequencing data, we can achieve a comprehensive understanding of genomic variation. Power your next discovery with Chromium™ Solutions that uncover the genome and exome data you've been missing. Now, you can resolve ambiguous single nucleotide variants, obtain phasing and haplotype information, identify structural variants, and assemble genomes without breaking a sweat.

Biology is challenging. Research is a race. Get there faster.

Learn more at [go.10xgenomics.com/linked-reads](http://go.10xgenomics.com/linked-reads)

**10X** GENOMICS®



---

## More data. One reaction.

---

**Totally on-target assay design.** The most intelligent targeted sequencing assay design ever. With comprehensive coverage of critical hotspot SNVs, contiguous tiled regions in coding sequences, and intron-exon boundaries in a revolutionary fast, simple, single-tube workflow, characterization and screening of your targets of interest is finally within reach. And on-target.

---

**Accel-Amplicon™  
Custom NGS Panels**

**Swift**  
BIOSCIENCES™

[swiftbiosci.com](http://swiftbiosci.com)



## Gene panels on demand, how and when you want them

**Ion AmpliSeq On-Demand Panels help you get more from targeted next-generation sequencing**

- **Now more selection**—build custom panels from a growing catalog of **over 5,000 pretested genes** most relevant in inherited disease research\*
- **Now more sizes**—order the exact quantity you need: 8, 24, 32, and 96 reactions per pack

With practical pack sizes that help lower up-front cost, and a powerful content selection engine that automates optimal gene selection, Ion AmpliSeq™ On-Demand Panels help you do targeted sequencing in your own lab, your own way.

Do targeted sequencing your way at [ampliseq.com](http://ampliseq.com)

Learn more at [thermofisher.com/ampliseqondemand](http://thermofisher.com/ampliseqondemand)




# GoodView<sup>TM</sup> Nucleic Acid Stain

## ——An alternative to EB

GoodView<sup>TM</sup> is a new nucleic acid stain, an alternative to the traditional ethidium bromide (EB) stain for detecting nucleic acid in agarose gels. It emits green fluorescence when bound to DNA or RNA. This new stain has two fluorescence excitation maxima when bound to nucleic acid, one centered at 268 nm and another at 294 nm. In addition, it has one visible excitation at 491 nm. The Fluorescence emission of GoodView<sup>TM</sup> bound to DNA is centered at 530 nm.

### Comparative sensitivity test of GV and EB




The result of electrophoresis demonstrates GV is almost as sensitive as EB.

The Test Report from Institute for Environmental Health and Related Product Safety of Chinese Center for Disease Control and Prevention concludes that:

- ◆ Acute Oral Toxicity Test: GoodView<sup>TM</sup> Nucleic Acid Stain belongs to nontoxic.
- ◆ Mouse Marrow Chromophilous Erythrocyte Micronucleus Test: Negative. There is no significant difference in the incidence of micronuclei between test and control groups.
- ◆ Ames Test: Negative. No mutagenicity was observed.
- ◆ In Vitro Mammalian Cell Chromosome Aberration Test: Negative. No increasing aberration rate was observed.

The test report is available upon request.

A large, abstract image of blue liquid droplets and bubbles on a white background, occupying the left two-thirds of the page.

Echo® Acoustic LIQUID HANDLING

for GENOMICS



Reduce Library Prep Costs

# 100-Fold

Echo® Liquid Handlers enable library preparation in low microliter volumes for a range of sequencing methods. Dramatically reduce reagent costs, conserve samples, and eliminate steps – all while improving library quality.

## Echo acoustic liquid handling allows...

- ▶ 100-fold reduction of library prep reaction volumes
- ▶ 30-fold reduction of sample pooling turnaround time
- ▶ Increased sample throughput
- ▶ Automation of workflow to easily prepare thousands of samples
- ▶ Improved accuracy of results

## Comparison of Liquid Handling Methods\*

	Manual Pipetting	Echo® Liquid Handler
Amount of DNA	50 ng	0.06 – 2.0 ng
DNA volume (Rxn)	25 µL	200 nL
Library prep volume (Rxn)	25 µL	300 nL
Total volume	50 µL	0.5 µL
Reactions per kit	96	9600
Cost per reaction	\$72.91	\$0.73

For more information, visit [www.labcyte.com/sequencing](http://www.labcyte.com/sequencing).

\* Low-Cost, High-Throughput Sequencing of DNA Assemblies Using a Highly Multiplexed Nextera Process. Shapland et al. ACS Synth. Biol., 2015

© 2018 LABCYTE INC. All rights reserved. Labcyte®, Echo®, and the Labcyte logo are registered trademarks or trademarks of Labcyte Inc., in the U.S. and/or other countries.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

**LABCYTE**   
The Future of Science is Sound

 [@LabcyteInc](https://twitter.com/LabcyteInc)  
[info-us@labcyte.com](mailto:info-us@labcyte.com)

It's a new transfection reagent,  
not just another one

## Helix-IN™ DNA Transfection Reagent

OZ Biosciences revolutionizes polymer-based transfection with the design of a novel patented **Cationic Hydroxylated Amphiphilic Multi-block Polymer (CHAMP™ Technology)**.

Helix-IN™ reagent, biocompatible & biodegradable, opens up new possibilities for addressing issues of classical transfection technologies.


Preserve Viability, Reduce Cellular Stress & Experience High Efficiency

**REQUEST  
FREE SAMPLE**

Limited-time offer - use code JDV

[contact@ozbiosciences.com](mailto:contact@ozbiosciences.com)





# CRISPR-Cas

## A Laboratory Manual



The essential guide to CRISPR-Cas

Edited by Jennifer Doudna, *University of California, Berkeley*;  
Prashant Mali, *University of California, San Diego*

The development of CRISPR-Cas technology is revolutionizing biology. Based on machinery bacteria use to target foreign nucleic acids, these powerful techniques allow investigators to edit nucleic acids and modulate gene expression more rapidly and accurately than ever before.

Featuring contributions from leading figures in the CRISPR-Cas field, this laboratory manual presents a state-of-the-art guide to the technology. It includes step-by-step protocols for applying CRISPR-Cas-based techniques in various systems, including yeast, zebrafish, *Drosophila*, mice, and cultured cells (e.g., human pluripotent stem cells). The contributors cover web-based tools and approaches for designing guide RNAs that precisely target genes of interest, methods for preparing and delivering CRISPR-Cas reagents into cells, and ways to screen for cells that harbor the desired genetic changes. Strategies for optimizing CRISPR-Cas in each system—especially for minimizing off-target effects—are also provided.

Authors also describe other applications of the CRISPR-Cas system, including its use for regulating genome activation and repression, and discuss the development of next-generation CRISPR-Cas tools. The book is thus an essential laboratory resource for all cell, molecular, and developmental biologists, as well as biochemists, geneticists, and all who seek to expand their biotechnology toolkits.

2016, 192 pages, illustrated (20 color, 4 B&W), index

Paperback: Print Book + eBook \$210

Print Book \$110

eBook \$100

ISBN 978-1-621821-31-1

Hardcover: Print Book + eBook \$250

Print Book \$150

eBook \$100

ISBN 978-1-621821-30-4

Visit our website for special sale pricing!

eBook available exclusively at [www.cshlpress.org](http://www.cshlpress.org)

### Contents

Preface

#### CHAPTER 1 Overview of CRISPR-Cas9 Biology

INTRODUCTION  
Overview of CRISPR-Cas9 Biology  
*Hannah K. Ratner, Timothy R. Sampson, and David S. Weiss*

#### CHAPTER 2 Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems

INTRODUCTION  
Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems

*Alexandra E. Briner and Rudolphe Barrangou*

#### PROTOCOL

Prediction and Validation of Native and Engineered Cas9 Guide Sequences  
*Alexandra E. Briner, Emily D. Henriksen, and Rudolphe Barrangou*

#### CHAPTER 3 Characterization of Cas9-Guide RNA Orthologs

INTRODUCTION

Characterization of Cas9-Guide RNA Orthologs  
*Jonathan L. Braff, Stephanie J. Yaung, Kevin M. Esvelt, and George M. Church*

#### PROTOCOL

Characterizing Cas9 Protospacer-Adjacent Motifs with High-Throughput Sequencing of Library Depletion Experiments  
*Jonathan L. Braff, Stephanie J. Yaung, Kevin M. Esvelt, and George M. Church*

#### CHAPTER 4 Large-Scale Single Guide RNA Library Construction and Use for CRISPR-Cas-Based Genetic Screens

INTRODUCTION

Large-Scale Single Guide RNA Library Construction and Use for CRISPR-Cas9-Based Genetic Screens  
*Tim Wang, Eric S. Lander, and David M. Sabatini*

#### PROTOCOLS

Single Guide RNA Library Design and Construction  
*Tim Wang, Eric S. Lander, and David M. Sabatini*

Viral Packaging and Cell Culture for CRISPR-Based Screens  
*Tim Wang, Eric S. Lander, and David M. Sabatini*

#### CHAPTER 5 Adeno-Associated Virus-Mediated Delivery of CRISPR-Cas Systems for Genome Engineering in Mammalian Cells

#### PROTOCOL

Adeno-Associated Virus-Mediated Delivery of CRISPR-Cas Systems for Genome Engineering in Mammalian Cells  
*Thomas Gaj and David V. Schaffer*

#### CHAPTER 6 Detecting Single-Nucleotide Substitutions Induced by Genome Editing

#### INTRODUCTION

Detecting Single-Nucleotide Substitutions Induced by Genome Editing  
*Yuichiro Miyaoka, Amanda H. Chan, and Bruce R. Conklin*

#### PROTOCOL

Using Digital Polymerase Chain Reaction to Detect Single-Nucleotide Substitutions Induced by Genome Editing  
*Yuichiro Miyaoka, Amanda H. Chan, and Bruce R. Conklin*

#### CHAPTER 7 CRISPR-Cas9 Genome Engineering in *Saccharomyces cerevisiae* Cells

#### PROTOCOL

CRISPR-Cas9 Genome Engineering in *Saccharomyces cerevisiae* Cells  
*Owen W. Ryan, Snigdha Poddar, and Jamie H.D. Cate*

#### CHAPTER 8 Cas9-Mediated Genome Engineering in *Drosophila melanogaster*

#### INTRODUCTION

Cas9-Mediated Genome Engineering in *Drosophila melanogaster*  
*Benjamin E. Housden and Norbert Perrimon*

#### PROTOCOLS

Design and Generation of Donor Constructs for Genome Engineering in *Drosophila*  
*Benjamin E. Housden and Norbert Perrimon*

Detection of Indel Mutations in *Drosophila* by High-Resolution Melt Analysis (HRMA)  
*Benjamin E. Housden and Norbert Perrimon*

Design and Generation of *Drosophila* Single Guide RNA Expression Constructs  
*Benjamin E. Housden, Yanhui Hu, and Norbert Perrimon*

#### CHAPTER 9 Optimization Strategies for the CRISPR-Cas9 Genome-Editing System

#### INTRODUCTION

Optimization Strategies for the CRISPR-Cas9 Genome-Editing System  
*Charles E. Vejnar, Miguel Moreno-Mateos, Daniel Cifuentes, Ariel A. Bazzini, and Antonio J. Giraldez*

#### PROTOCOL

Optimized CRISPR-Cas9 System for Genome Editing in Zebrafish  
*Charles E. Vejnar, Miguel Moreno-Mateos, Daniel Cifuentes, Ariel A. Bazzini, and Antonio J. Giraldez*

#### CHAPTER 10 Editing the Mouse Genome Using the CRISPR-Cas9 System

#### INTRODUCTION

Editing the Mouse Genome Using the CRISPR-Cas9 System  
*Adam Williams, Jorge Henao-Mejia, and Richard A. Flavell*

#### PROTOCOL

Generation of Genetically Modified Mice Using the CRISPR-Cas9 Genome-Editing System  
*Jorge Henao-Mejia, Adam Williams, Anthony Rongvaux, Judith Stein, Cynthia Hughes, and Richard A. Flavell*

#### CHAPTER 11 Genome Editing in Human Pluripotent Stem Cells

#### INTRODUCTION

Genome Editing in Human Pluripotent Stem Cells  
*Cory Smith, Zhaohui Ye, and Linzhao Cheng*

#### PROTOCOL

A Method for Genome Editing in Human Pluripotent Stem Cells  
*Cory Smith, Zhaohui Ye, and Linzhao Cheng*

#### CHAPTER 12 An Introduction to CRISPR Technology for Genome Activation and Repression in Mammalian Cells

#### INTRODUCTION

An Introduction to CRISPR Technology for Genome Activation and Repression in Mammalian Cells  
*Dan Du and Lei S. Qi*

#### PROTOCOL

CRISPR Technology for Genome Activation and Repression in Mammalian Cells  
*Dan Du and Lei S. Qi*

APPENDIX General Safety and Hazardous Material Information  
*Dan Du and Lei S. Qi*

#### INDEX



[www.cshlpress.org](http://www.cshlpress.org)


Introducing



# Engineered Cells

SYNTHEGO

Full Stack  
Genome  
Engineering



[Synthego.com/cells](https://Synthego.com/cells)



11th AACR Conference on

# THE SCIENCE OF CANCER HEALTH DISPARITIES IN RACIAL/ETHNIC MINORITIES AND THE MEDICALLY UNDERSERVED

November 2-5, 2018 | Sheraton New Orleans Hotel | New Orleans, LA

**Submit an Abstract By:** Wednesday, July 18, 2018

**Register and Save By:** Tuesday, September 18, 2018

## CONFERENCE COCHAIRS



**Ivis Febus-Sampayo**  
SHARE Cancer Support,  
New York, NY



**Augusto C. Ochoa**  
Louisiana State University  
Health Sciences Center, New Orleans, LA



**Laura Fejerman**  
University of California, San Francisco  
School of Medicine, San Francisco, CA



**Brian M. Rivers**  
Morehouse School of Medicine, Atlanta, GA



**Scarlett Lin Gomez**  
University of California, San Francisco  
School of Medicine, San Francisco, CA

## ABOUT THIS CONFERENCE

The AACR Science of Cancer Health Disparities conferences advance the understanding of, and ultimately help to eliminate, the disparities that represent a major public health problem in our country. Reflecting this transdisciplinary field, professionals from academia, industry, government, and the community are brought together to promote the exchange of novel ideas, discuss the latest findings in the field, and stimulate the development of new research on cancer health disparities.



Continuing Medical Education (CME) Activity-AMA PRA Category 1 Credits™ available






Learn more and register at  
[AACR.org/Disparities18](http://AACR.org/Disparities18)

#AACRDISP18



American Association  
for Cancer Research®

FINDING CURES TOGETHER®



# 2018 SCIENTIFIC CONFERENCES

Presenting the most significant research on cancer etiology, prevention, diagnosis, and treatment

## 12th Biennial Ovarian Cancer Research Symposium

Conference Cochairs: Frances R. Balkwill, Mary L. (Nora) Disis, Pamela S. Ohashi, and Elizabeth M. Swisher  
September 13-15, 2018 | Seattle, WA

## Pancreatic Cancer: Advances in Science and Clinical Care

Conference Cochairs: Ronald M. Evans, Manuel Hidalgo, Steven D. Leach, Gloria M. Petersen, and Brian M. Wolpin  
September 21-24, 2018 | Boston, MA

## Second AACR International Conference on Translational Cancer Medicine

Conference Cochairs: Carlos L. Arteaga, Carlos Gil M. Ferreira, and Gabriel A. Rabinovich  
September 27-29, 2018 | São Paulo, Brazil

## Intestinal Stem Cells and Colon Cancer: Biology to Therapy

Conference Cochairs: Anil K. Rustgi, Johanna Bendell, Hans Clevers, Christina Curtis, and Owen Sansom  
September 27-30, 2018 | Washington, DC

## Metabolism and Cancer

Conference Cochairs: Ralph J. Deberardinis, Tak W. Mak, Joshua D. Rabinowitz, and M. Celeste Simon  
September 28-October 1, 2018 | New York, NY

## Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Conference Cochairs: Nina Bhardwaj, Christoph Huber, Elizabeth M. Jaffee, and Guido Kroemer  
September 30-October 3, 2018 | New York, NY

## EACR-AACR-ISCR Conference: The Cutting Edge of Contemporary Cancer Research

Conference Cochairs: Richard M. Marais, Eli Pikarsky, and Robert A. Weinberg  
October 9-11, 2018 | Jerusalem, Israel

## 30th Anniversary AACR Special Conference

**Convergence: Artificial Intelligence, Big Data and Prediction in Cancer**  
Conference Cochairs: Phillip A. Sharp and William C. Hahn  
October 14-17, 2018 | Newport, RI

## 11th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

Conference Cochairs: Ivis Febus-Sampayo, Laura Fejerman, Scarlett Lin Gomez, Augusto C. Ochoa, and Brian M. Rivers  
November 2-5, 2018 | New Orleans, LA

## EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Scientific Committee Cochairs: Charles Swanton, James L. Gulley, and Antoni Ribas  
November 13-16, 2018 | Dublin, Ireland

## AACR-KCA Joint Conference on Precision Medicine in Solid Tumors

Program Committee Cochairs: Tae-You Kim and Charles L. Sawyers  
November 15-17, 2018 | Seoul, South Korea

## Tumor Immunology and Immunotherapy

Conference Cochairs: James P. Allison, Lisa M. Coussens, Ira Mellman, and Drew M. Pardoll  
November 27-30, 2018 | Miami Beach, FL

## Innovation and Biomarkers in Cancer Drug Development: A Joint Meeting Presented By EORTC, NCI, EMA, and AACR

Organizing Committee Chair: Denis A. Lacombe  
November 29-30, 2018 | Brussels, Belgium

## Targeting PI3K/mTOR Signaling


Conference Cochairs: Lewis C. Cantley, David M. Sabatini, and Jean J. Zhao  
November 30-December 3, 2018 | Boston, MA

Learn more and register at  
[AACR.org/Calendar](http://AACR.org/Calendar)

**AACR** American Association  
for Cancer Research®  
FINDING CURES TOGETHER®

# Eprobe® / Eprimer™

Novel fluorescent probe for  
SNP genotyping / somatic mutation detection



- A DNA-based probe which emits fluorescence when specifically binding to a complementary strand (Fig.1).
- Thiazole orange, one of the available fluorophores used by Eprobe increases melting temperature (Tm) of the probe by approx. 10°C.
- Fluorescence emitted by Eprobe can be detected using a filter for SYBR® Green I. \*SYBR is a registered trademark of Molecular Probes, Inc.




Figure 1. Fluorescence emission mechanism of Eprobe

## High resolution SNP detection with Eprobe

- Melting curve analysis after asymmetric PCR with Eprobe can detect genotype of SNP (Fig.2).
- Increased Tm of the Eprobe enables a shorter probe design and a clearer distinction of single nucleotide substitution.
- Predesigned Eprobes targeting SNP for ADH1B (rs1229984), ADRB2 (rs1042713), ALDH2 (rs671), FTO (rs9939609), UCP1 (rs1800592) and others are available.




Figure 2. Predesigned Eprobe for IL28B (rs8099917).

## Highly sensitive somatic mutation detection

- Highly sensitive detection of somatic mutations (down to 0.1%) can be achieved (Fig.3) by suppression of PCR amplification of wild-type alleles by Eprobe (PCR clamping).




Figure 3. Predesigned Eprobe for G12D in the KRAS gene.

## Pricing and ordering information

Product	Fluorophore	Quantity	List price
Eprobe	Thiazole Orange	1.5 nmol	¥19,000 <del>¥38,000</del>
		3.0 nmol	¥30,000 <del>¥60,000</del>
		5.0 nmol	¥45,000 <del>¥90,000</del>
		10.0 nmol	¥70,000 <del>¥140,000</del>
Modification: 3' Spacer C3.	Thiazole Pink	1.5 nmol	¥45,000
		3.0 nmol	¥70,000
		5.0 nmol	¥110,000
		10.0 nmol	¥170,000

- Excitation/Emission wave length (nm): Thiazole Orange: 510/530, Thiazole Pink: 570/590.
- Purification: HPLC, Shipping format: dry.
- Shipping charge: 11,000 JPY/ shipment.

Product	Fluorophore	Quantity	List price
Eprimer	Thiazole Orange	1.5 nmol	¥19,000 <del>¥38,000</del>
		3.0 nmol	¥30,000 <del>¥60,000</del>
		5.0 nmol	¥45,000 <del>¥90,000</del>
		10.0 nmol	¥70,000 <del>¥140,000</del>
3' unmodified: Extension from the 3' end is possible.	Thiazole Pink	1.5 nmol	¥45,000
		3.0 nmol	¥70,000
		5.0 nmol	¥110,000
		10.0 nmol	¥170,000

Special offer for new customers  
**50% OFF the list price!**  
All Thiazole orange-labeled products

Find out more at

[https://www.dnaform.jp/en/products/fluorescent\\_oligonucleotide/eprobe\\_eprimer/](https://www.dnaform.jp/en/products/fluorescent_oligonucleotide/eprobe_eprimer/)

 DNAFORM  
Precision gene technologies



## Dharmacon™ CRISPR reagents help you move forward. Faster.

Simplify your gene editing workflow with the Dharmacon™ Edit-R™ CRISPR-Cas9 platform. Custom or predesigned ready-to-use lentiviral and synthetic guide RNAs leverage a validated algorithm to select highly functional, specific targets for gene knockout – enabling you to quickly assess multiple target sites per gene across one or hundreds of genes.

**CRISPR Guide RNAs | CRISPR Screening Libraries | Cas9 Nucleases**

---

**crRNAs that have high functionality scores show high editing efficiency**



HEK293T-CAG-Cas9 cells were transfected with either high-scoring or low-scoring crRNAs (50 nM crRNA:tracrRNA) using DharmaFECT 1 transfection reagent (0.25 µL/well) in 96-well format. Gene editing efficiencies were determined using next-generation sequencing. 93% of the top 10 high-scoring crRNAs targeting ten different genes have > 40% indel formation and only 33% of the 10 lowest scoring designs have > 40% indel formation.